
Radiotherapy R&D partnership
French-US company Orano Med is developing Lead-212 (212Pb) Targeted Alpha Therapy, which combines the ability of biological molecules such as...

Sanofi licences vaccine against bacterial sepsis
Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causing approximately 10 million cases of invasive E. coli...

Neuraxpharm pays US$650m for MS drug commercialisation
Together with a fee of US$12.5m for the launch of the B cell suppressant antibody to treat relapsing/remitting mulitple sclerosis (rMS), the US$140m...

Spexis AG bags money for pivotal Phase III trial
The cash injection of US$2.5m that was led by SPRIM Global Investments (SGI) is urgently needed to finance US commercialisation of the company’s...

Mithra Pharmaceuticals SA in €17m licencing deal
Donesta is the first Estetrol-based hormone substitution therapy for the relief of menopausal vasomotor symptoms (VMS). Under a licencing deal with...

Valneva announces extension of existing loan agreement
An add-on loan provides Valneva SE with immediate access to $50m, with an additional $50m available in Q4/2023. According to the vaccine maker, the...

Nanobiotix SA licences NBTXR3 to J&J
NBTXR3 is currently being evaluated across different solid tumour indications including NANORAY‑312, a global Phase III pivotal study in ...